FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Info Collection on FOIA Identity Certifications

[ Price : $8.95]

Federal Register notice: FDA seeks comments on an information collection extension entitled Certification of Identity; Form FDA 39...

BioMarin Asked to Submit New Data on Gene Therapy

[ Price : $8.95]

BioMarin Pharmaceutical says FDA is requesting results from an upcoming three-year data analysis from the ongoing Phase 3 GENEr8-1...

Califf Comes Down With Covid-19

[ Price : $8.95]

FDA commissioner Robert Califf tests positive for Covid-19 while traveling over the weekend on agency business.

Guide on Early Studies on Cell/Gene Therapies

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled Studying Multiple Versions of a Cellular or Gene Therapy Pr...

Guide on Bioanalytical Method Validation

[ Price : $8.95]

Federal Register notice: FDA posts a final guidance entitled M10 Bioanalytical Method Validation and Study Sample Analysis.

GSK Blenrep Phase 3 Misses Primary Endpoint

[ Price : $8.95]

A Phase 3 trial of GSKs accelerated-approved Blenrep (belantamab mafodotin) in patients with relapsed or refractory multiple myelo...

FDA Places Hold on Verve Hypercholesterolemia Drug

[ Price : $8.95]

FDA slaps a clinical hold on a Verve Therapeutics IND for its VERVE-101 in patients with heterozygous familial hypercholesterolemi...

Verrica Pharma Refiling NDA for VP-102

[ Price : $8.95]

Verrica Pharmaceuticals says it is filing an NDA resubmission in the first quarter next year for VP-102 to treat molluscum contagi...

Guide on Studying Multiple Cell/Gene Therapies

[ Price : $8.95]

FDA releases a final guidance entitled Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical...